Business Description
Biosenic
ISIN : BE0974280126
Compare
Compare
Traded in other countries / regions
BIOS.BelgiumBT1.Germany0R55.UKBNZPF.USA IPO Date
2015-02-06Description
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | -1.63 | |||||
| Debt-to-Equity | -1.48 | |||||
| Debt-to-EBITDA | -1.14 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 67.7 | |||||
| 3-Year EPS without NRI Growth Rate | 72.5 | |||||
| 3-Year FCF Growth Rate | 75.8 | |||||
| 3-Year Book Growth Rate | -46.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.14 | |||||
| 9-Day RSI | 20.65 | |||||
| 14-Day RSI | 25.25 | |||||
| 6-1 Month Momentum % | -63.16 | |||||
| 12-1 Month Momentum % | -80.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.21 | |||||
| Quick Ratio | 0.21 | |||||
| Cash Ratio | 0.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -125.2 | |||||
| Shareholder Yield % | -316.95 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -476.87 | |||||
| ROA % | -130.37 | |||||
| ROIC % | -28.78 | |||||
| ROC (Joel Greenblatt) % | -1850.12 | |||||
| ROCE % | -299.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.25 | |||||
| EV-to-EBITDA | -1.25 | |||||
| EV-to-FCF | -7.95 | |||||
| Earnings Yield (Greenblatt) % | -80.12 | |||||
| FCF Yield % | -114.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biosenic Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.182 | ||
| Beta | -0.21 | ||
| Volatility % | 282.43 | ||
| 14-Day RSI | 25.25 | ||
| 14-Day ATR (€) | 0.002661 | ||
| 20-Day SMA (€) | 0.02247 | ||
| 12-1 Month Momentum % | -80.35 | ||
| 52-Week Range (€) | 0.012 - 0.189 | ||
| Shares Outstanding (Mil) | 195.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosenic Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosenic Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biosenic Frequently Asked Questions
What is Biosenic(XBRU:BIOS)'s stock price today?
The current price of XBRU:BIOS is €0.02. The 52 week high of XBRU:BIOS is €0.19 and 52 week low is €0.01.
When is next earnings date of Biosenic(XBRU:BIOS)?
The next earnings date of Biosenic(XBRU:BIOS) is .
Does Biosenic(XBRU:BIOS) pay dividends? If so, how much?
Biosenic(XBRU:BIOS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers